DelveInsight’s “Bullous Pemphigoid (BP) – Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the BP, historical and forecasted epidemiology as well as the BP market trends in the United States, the EU4 and the UK and Japan.
Bullous Pemphigoid Overview
According to the Cornea Research Foundation of America (2022), Bullous keratopathy is a condition where the cornea becomes permanently swollen. This occurs because the inner layer of the cornea, the endothelium, has been damaged and is not pumping fluid properly. The cause of endothelial damage could be trauma, glaucoma, or inflammation after eye surgery. The causes of bullous keratopathy have changed over the last two decades. Twenty years ago, the most common reason for bullous keratopathy was complications from cataract surgery with or without problems from intra-ocular lenses. Cataract surgery techniques and intra-ocular lens implants have improved dramatically over this period. Corneal problems are now less common after cataract surgery. Currently, one of the most common reasons for developing bullous keratopathy, or secondary corneal decompensation, is related to problems due to glaucoma surgery. Subepithelial fluid-filled bullae form on the corneal surface as the corneal stroma (the deeper dense connective tissue layer of the cornea) swells, leading to decreased visual acuity, loss of contrast, glare, and photophobia. Sometimes bullae rupture, causing pain and foreign body sensation. Bacteria can invade a ruptured bulla, leading to a corneal ulcer.
Bullous Pemphigoid Epidemiology Insights
In a study by Shimazaki et al. (2007), the most common cause of bullous keratopathy was cataract surgery (pseudophakic or aphakic BK: PBK/ABK, n=428, 44.4%), followed by laser iridotomy (LI, n=225, 23.4%), glaucoma surgery other than LI (n=51, 5.3%), trauma (n=40, 4.2%), glaucoma (n=26, 2.7%), and vitrectomy (n=21, 2.2%).
According to the American Academy of Ophthalmology (2022), it is estimated that 1-2 % of people undergoing cataract surgery will develop persistent post-operative edema. Old surgical techniques and intraocular lens designs were associated with higher numbers of postoperative corneal edema. Preoperative endothelial cell count and surgical trauma are the most important factors for developing PBK.
Click here to learn more about the Bullous Pemphigoid Market Landscape
The Report Covers the Bullous Pemphigoid Epidemiology Segmented by:
Bullous Pemphigoid prevalent cases
Bullous Pemphigoid diagnosed cases
Bullous Pemphigoid treatment cases
Bullous Pemphigoid incident cases
Bullous Pemphigoid cases based on age
Key Companies Working in the Bullous Pemphigoid Market
Gilead Sciences
Takeda
Pfizer
GlaxoSmithKline
And many others
Bullous Pemphigoid Therapies Covered and Analyzed in the Report:
Filgotinib
CT-P13
Remicade
Infliximab
MT-1303
Learn more about the Key Companies and Emerging Therapies in the Bullous Pemphigoid Market.
Table of Contents
Key Insights
Bullous Pemphigoid Introduction
Executive Summary of Bullous Pemphigoid
Disease Background and Overview
Epidemiology and patient population
Bullous Pemphigoid Emerging Therapies
Bullous Pemphigoid Market Outlook
Market Access and Reimbursement of Therapies
Market Drivers
Market Barriers
Appendix
Report Methodology
DelveInsight Capabilities
Disclaimer
Learn about the detailed offerings of the report @ Bullous Pemphigoid Market Outlook.
Media ContactCompany Name: DelveInsight Business ResearchContact Person: Adya KaulEmail: Send EmailPhone: 9193216187Address:304 S. Jones Blvd #2432 City: Las VegasState: NevadaCountry: United StatesWebsite: https://www.delveinsight.com/consulting